Given that a goal of this study was to examine the relationship between HRD and platinum-based clinical outcomes, we sought to increase the sample size by including all patients in these two disease sites where HRD is an emerging biomarker despite the differences in histologies (including EGFR or ALK mutation status in lung cancer) and treatment histories. The gene discussed is EGFR; the disease is lung cancer.